当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Neoadjuvant chemotherapy in oesophageal adenocarcinoma – Authors' reply
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1470-2045(17)30776-3 Derek Alderson 1 , Matthew Nankivell 2 , Ruth Langley 2 , David Cunningham 3
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1470-2045(17)30776-3 Derek Alderson 1 , Matthew Nankivell 2 , Ruth Langley 2 , David Cunningham 3
Affiliation
In response to the comments about the UK MRC OE05 trial,1 we acknowledge the ongoing debate about the treatment of patients with oesophageal adenocarcinoma.
中文翻译:
食管腺癌的新辅助化疗——作者的回复
作为对英国 MRC OE05 试验评论的回应1 ,我们承认关于食管腺癌患者治疗的持续争论。
更新日期:2017-11-01
中文翻译:
食管腺癌的新辅助化疗——作者的回复
作为对英国 MRC OE05 试验评论的回应1 ,我们承认关于食管腺癌患者治疗的持续争论。